Relmada Therapeutics, Inc. RLMD Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
- Relmada Therapeutics, Inc. (RLMD) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $2.1 in Q1 2026.